No Data
No Data
Anhui Wanbang Pharmaceutical Technology: Half-year report for the year 2024.
Anhui Wanbang Pharmaceutical Technology: Summary of Half-Year Report in 2024.
Wanbang Medicine (301520.SZ): The net income in the first half of the year was 55.03296 million yuan, a year-on-year increase of 2.25%.
On August 22nd, Wangbang Medicine (301520.SZ) announced its half-year report for 2024. During the reporting period, the revenue was 0.187 billion yuan, an increase of 13.47% compared to the same period last year. The net income attributable to shareholders of the listed company was 55.03296 million yuan, a year-on-year increase of 2.25%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 41.3276 million yuan, a year-on-year decrease of 20.11%. The basic earnings per share were 0.83 yuan.
Wonbon Pharma (301520.SZ): The company has no drug development for monkeypox virus.
On August 16, Gelunhui reported that Wanbang Medicine (301520.SZ) stated on its investor platform that the company does not have any drug research and development for monkeypox virus.
Wanbang Pharma (301520.SZ): No research and development of drugs for COVID-19.
On August 9th, Gelon Hui reported that Wanbang Medicine (301520.SZ) stated on the investor interactive platform that it has not conducted research and development of drugs for the coronavirus.
Wanbang Pharmaceutical (301520.SZ): No synthetic biotechnology available at the moment.
On July 31st, Gelonhui reported that Wanbang Pharmaceutical (301520.SZ) stated on an investor interaction platform that the company currently does not have any biotechnology synthesis.
No Data
No Data